Related Experiment Video

Updated: Jun 10, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Present state of target therapy for disseminated renal cell carcinoma

Sandra Waalkes1, Mario Kramer, Thomas Rw Herrmann

  • 1Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.

Immunotherapy
|July 20, 2010
PubMed

Insights

Targeted therapy has advanced kidney cancer treatment, offering new options for metastatic renal cell carcinoma. This review covers current targeted agents and the potential role of surgery alongside systemic therapy.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is often resistant to traditional treatments like chemotherapy and radiotherapy.
  • The advent of targeted therapy has significantly advanced the management of advanced metastatic RCC.
  • RCC serves as a key model for developing and assessing novel targeted drugs.

Purpose of the Study:

  • To review currently available targeted therapy agents for metastatic renal cell carcinoma.
  • To summarize evidence-based data on the effectiveness of these agents.
  • To explore the role of debulking tumor nephrectomy combined with systemic therapy in treatment algorithms.

Main Methods:

  • Literature review of experimental and clinical research.
  • Analysis of evidence-based data on targeted therapy effectiveness.
  • Evaluation of treatment algorithms including surgical and systemic approaches.

Main Results:

  • Targeted therapies have shown promise in treating advanced metastatic RCC.
  • Effectiveness data for various targeted agents are available.
  • The combination of debulking tumor nephrectomy and systemic therapy is under investigation.

Conclusions:

  • Targeted therapy is a cornerstone in treating advanced metastatic renal cell carcinoma.
  • Further research is needed to optimize treatment strategies, including the role of surgery.
  • Personalized treatment approaches are crucial for improving patient outcomes.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.